Epidermodysplasia verruciformis

Author: Vanessa Ngan, Staff Writer, 2006. Updated by Dr Jannet Gomez, December 2016.

What is epidermodysplasia verruciformis?

Epidermodysplasia verruciformis (EV) is a rare, autosomal recessive inherited skin disorder characterised by eruptions of wart-like lesions that may occur anywhere on the body. These lesions are caused by infection with the human papillomavirus (HPV). There are over 70 subtypes of HPV that are responsible for causing a wide range of viral warts. In the general population infection with some subtypes of HPV have minimal or no clinical effect, however in patients with EV, infection with these same subtypes can cause flat, wart-like lesions. It has been found that patients with EV have an abnormal or impaired immune response to HPV or wart viruses. In patients with EV more than 30 subtypes of HPV have been implicated.

A major concern for patients with EV is that the wart-like lesions may transform into skin cancers. Exposure to sunlight or UV rays appears to be involved in the progression from benign warts or verrucae to malignant skin cancers. It has also been discovered that the potential for EV lesions to turn into cancers may depend on the type of HPV infection present. Over 90% of EV-associated skin cancers contain HPV types 5, 8, 10, and 47. EV lesions caused by HPV 14, 20, 21, and 25 usually remain benign (non-cancerous) skin lesions.

Who gets epidermodysplasia verruciformis?

EV is an autosomal recessive inherited disorder, which means that 2 abnormal EV genes (one from each parent) are needed to have the disease. It has been found that 10% of patients with EV come from marriages between blood relatives (i.e. the parents share a common ancestor). In a few cases sex-linked and autosomal dominant inheritance patterns have also been found.

Mutations in the EVER1 or EVER2 genes on chromosome 17q25 has been linked in  development of  EV. This mutation decreases cell capacity to fight HPV infections. However there are cases of EV that lack this mutationMutations in Ras homolog gene family member H (RHOH), MST1 deficiency, splicing deficiency in the gene encoding LCK (lymphocyte specific kinase)  are noted in sporadic cases.

The warts usually start to develop sometime during childhood. About 7.5% of cases appear in infancy, 61.5% in children aged 5-11 years and 22.5% in puberty. The disease affects both males and females and people of all races.

A similar disorder, known as acquired epidermodysplasia verruciformis, may arise in patients with impaired immunity, for example as a result of HIV infection, organ transplantation or a lymphoma.

What are the clinical features of epidermodysplasia verruciformis?

Two types of EV lesions have been described.

  • Flat, wart-like lesion that look like plane warts. These can be flat-topped papules ranging from light pink to violet in colour. In some places papules may join together to form large plaques. These may be reddish brown and have scaly surfaces and irregular borders but can also be hypopigmented or hyperpigmented.
  • Verrucous or seborrhoeic keratoses-like lesions. These are most commonly seen on sun-exposed skin and are often slightly raised, brown coloured lesions. They have a greater tendency to become malignant than the plane wart type of EV lesion.

Flat wart-like lesions also commonly appear on sun-exposed areas such as the hands, feet, face, and ear lobes. Plaque-like lesions usually appear on the trunk, neck, arms and legs. The palms, soles, armpits and external genitals may also be involved.

In most cases the warts occur in clusters and can be anything from a few warts to over a hundred warts.

What is the treatment for epidermodysplasia verruciformis?

EV is a lifelong disease. Even though lesions can be treated or removed as they appear, patients with EV will continue to develop these lesions throughout life. In many cases lesions may develop and remain unchanged for years. The greatest risk is that in 30-60% of EV patients these lesions will change into skin cancers; these are mostly squamous cell carcinoma and intraepidermal carcinoma; basal cell carcinoma and and adnexal tumours are less common. Malignant tumours are usually found in patients 30–50 years of age.

Currently there is no treatment to prevent new EV lesions from occurring. The management of EV involves a combination of medical and surgical treatments alongside patient counselling, education and regular surveillance (especially if immunocompromised).

  • Stress the importance of following sun protection strategies especially if living at high altitude and/or working outdoors. Exposure to sunlight (UVB and UVA) has been shown to increase the rate of EV lesions turning into skin cancers.  
  • Treat and remove warts, as you would treat other viral warts. This includes chemical treatment, cryotherapy with liquid nitrogen, electrosurgery and laser ablation.
  • Oral and topical retinoids (isotretinoin and acitretin), fluorouracil and imiquimod are proving to be useful agents.
  • Experimental therapies for EV lesions and skin tumours include intralesional interferons and retinoids, combination of isotretinoin and interferon alpha or cholecalciferol (vitamin D) analogues.
  • Surgical excision and reconstruction are used for invasive skin cancers.

Contribute to Dermnet

Did you find this page useful? We want to continue to deliver accurate dermatological information to health professionals and their patients — for free. Funding goes towards creating articles for DermNet, supporting researchers, and improving dermatological knowledge around the world.

Donate now with credit card or Paypal


Related information



  • OMIM – Online Mendelian Inheritance in Man (search term Epidermodysplasia verruciformis)
  • Book: Textbook of Dermatology. Ed Rook A, Wilkinson DS, Ebling FJB, Champion RH, Burton JL. Fourth edition. Blackwell Scientific Publications.
  • Kalińska-Bienias A, Kowalewski C, Majewski S. The EVER genes – the genetic etiology of carcinogenesis in epidermodysplasia verruciformis and a possible role in non-epidermodysplasia verruciformis patients. Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii. 2016;33(2):75-80. doi:10.5114/ada.2016.59145. PubMed.
  • de Oliveira, W.R., Festa Neto, C., Rady, P.L., and Tyring, S.K. Clinical aspects of epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol. 2003; 17: 394–398. PubMed.
  • Crequer A, Troeger A, Patin E, Ma CS, Picard C, Pedergnana V, et al. Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Invest. 2012 Sep. 122 (9):3239-47. PubMed.
  • Crequer A, Picard C, Patin E, D'Amico A, Abhyankar A, Munzer M, et al. Inherited MST1 deficiency underlies susceptibility to EV-HPV infections. PLoS One. 2012. 7 (8):e44010. PubMed.
  • Li SL, Duo LN, Wang HJ, Dai W, Zhou EH, Xu YN, et al. Identification of the LCK mutation in an atypical epidermodysplasia verruciformis family with T cell defects and virus-induced squamous cell carcinoma. Br J Dermatol. 2016 Apr 18. PubMed.
  • Agrawal, Prachi G., et al. Epidermodysplasia verruciformis: An unusual malignant transformation. Indian Journal of Dermatology, Venereology, and Leprology 79.1 (2013): 97. PubMed.
  • Hoffner MV, Camacho FM. Surgical treatment of epidermodysplasia verruciformis. Dermatol Surg. 2010 Mar. 36(3):363-7. PubMed.

On DermNet NZ

Other websites:

Books about skin diseases:

See the DermNet NZ bookstore